The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
There is a strong interest in deciphering the role of non-coding RNAs in disease causality, progression, and therapeutic targeting. To satisfy this growing interest, over 200 databases have been created. However, only a handful of these repositories are maintained systematically and being updated periodically. Previous reviews have listed lncRNA databases associated with cardiovascular diseases, the most recent of these being in 2016. In this age of fast-paced genomic discoveries, it is important to periodically assess the repositories for updates and extended functionalities. All the databases reviewed in this paper have been updated at least once since January 2018. We have used some prominent ncRNAs related to CVDs as examples to investigate the salient features in each of these repositories. You can access the full review paper here .
Thu, 19 November
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
